Oct 11, 2017 – Izun Pharmaceuticals Corporation (“Izun”, “Company”, izunpharma.com), a clinical stage company focused on developing high efficacy products based on pharmaceutically active compounds derived from botanical sources, announced that the results from a recently completed double blind, Phase 2 clinical study, in oral mucositis, indicated promising positive outcomes for the investigational product IZN-6N4. The study was conducted at 12 centers in the United States and Israel. The trial enrolled a total of 110 patients with head and neck cancer who were scheduled to receive standard regimens of concomitant chemoradiation. Not only did patients treated with IZN-6N4 have less mouth and throat pain, as well as less soreness than controls, but importantly, they were also more able to maintain their weights throughout the course of radiotherapy. The data supports that the best efficacy of IZN-6N4 was related to its initiation of use at the start of chemoradiation.
Izun Pharmaceuticals is dedicated to harnessing nature’s complexity through the use of modern science to create and optimize botanical pharmaceutical products for the consumer health care industry.
For more information, see Businesswire http://www.businesswire.com/news/home/20171011005127/en/Izun-Pharmaceuticals-Announces-Positive-Results-Phase-2